{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:14:19Z","timestamp":1783498459991,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00415-026-13978-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:35:38Z","timestamp":1782448538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study"],"prefix":"10.1007","volume":"273","author":[{"given":"John","family":"Vissing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-0881","authenticated-orcid":false,"given":"Sheryl","family":"Pease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Scippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Ramchandren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"13978_CR1","unstructured":"Cairns E (2025). Updated: immunovant will not take rare disease drug to regulators despite phase 3 win., Endpoints News,. Available at: endpts.com\/immunovant-will-not-take-immune-drug-to-regulators-despite-phase-3-success\/. Last accessed 25 Mar 2025"},{"key":"13978_CR2","unstructured":"European Medicines Agency. Summary of product characteristics (SmPC): IMAAVY\u00ae\u00a0(nipocalimab). 2025. Available at:\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imaavy-epar-product-information_en.pdf. (Last accessed: Dec 2025)."},{"key":"13978_CR3","unstructured":"EuroQol Research Foundation, EQ-5D-5L user guide (2019), Version 3.0 September 2019. Available online: https:\/\/euroqol-domain.ams3.digitaloceanspaces.com\/wp-content\/uploads\/2025\/01\/08035109\/EQ-5D-5LUserguide-23-07.pdf. Accessed on 13 Aug 2025."},{"key":"13978_CR4","unstructured":"Myasthenia Gravis Foundation of America. MG-QoL 15r form. Available online: https:\/\/myasthenia.org\/Portals\/0\/MGQOL15r.pdf. Accessed on 14 Aug 2025."},{"key":"13978_CR5","unstructured":"National Institute of Neurological Disorders and Stroke. User manual for the quality of life in neurological disorders (Neuro-QoL) measures (Version 3.0). Available Online:\u00a0https:\/\/www.healthmeasures.net\/images\/neuro_qol\/User_and_scoring_guides\/Neuro-QOL_User_Manual_v3_26Apr2021_FINAL.pdf. Accessed on 14 Aug 2025."},{"key":"13978_CR6","unstructured":"Nipocalimab US PI available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761430s000lbl.pdf (last accessed date 19 Dec 2025)."},{"key":"13978_CR7","unstructured":"Sheryl Pease. Assessing the suitability of the Neuro-QoL Fatigue to evaluate fatigue in patients living with Myasthenia Gravis. Presented at the American Association of Neuromuscular & Electrodiagnostic Medicine 2024; Savannah, GA, USA; October 15\u201318, 2024. Available at: https:\/\/www.jnjmedicalconnect.com\/media\/attestation\/congresses\/neuroscience\/2024\/aanem\/assessing-the-suitability-of-the-neuroqol-fatigue-to-evaluate-fatigue-in-patients-living-with-gmg.pdf"},{"key":"13978_CR8","unstructured":"SOLIRIS (eculizumab) injection, for intravenous use. Prescribing information. 2024, Alexion Pharmaceuticals, Inc. Available Online: https:\/\/alexion.com\/Documents\/Soliris_USPI.pdf. Accessed on 14 Aug 2025."},{"key":"13978_CR9","unstructured":"ZILBRYSQ (zilucoplan) injection, for subcutaneous use. Prescribing information. 2023, UCB, Inc. Available online: https:\/\/www.ucb-usa.com\/zilbrysq-prescribing-information.pdf. Accessed on 14 Aug 2025."},{"key":"13978_CR10","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s00415-021-10902-1","volume":"269","author":"LK Andersen","year":"2022","unstructured":"Andersen LK, Jakobsson AS, Revsbech KL, Vissing J (2022) Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol 269:3086\u20133093. https:\/\/doi.org\/10.1007\/s00415-021-10902-1","journal-title":"J Neurol"},{"key":"13978_CR11","doi-asserted-by":"publisher","first-page":"e207937","DOI":"10.1212\/wnl.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V et al (2024) Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study. Neurology 102:e207937. https:\/\/doi.org\/10.1212\/wnl.0000000000207937","journal-title":"Neurology"},{"key":"13978_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S et al (2025) Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol 24:105\u2013116. https:\/\/doi.org\/10.1016\/s1474-4422(24)00498-8","journal-title":"Lancet Neurol"},{"key":"13978_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ (2018) Measuring clinical treatment response in myasthenia gravis. Neurol Clin 36:339\u2013353. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.006","journal-title":"Neurol Clin"},{"key":"13978_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L et al (1998) Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 841:769\u2013772. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11015.x","journal-title":"Ann N Y Acad Sci"},{"key":"13978_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/cnd.0000000000000377","volume":"23","author":"S Beladakere Ramaswamy","year":"2021","unstructured":"Beladakere Ramaswamy S, Singh S, Hooshmand S et al (2021) Current and upcoming treatment modalities in myasthenia gravis. J Clin Neuromuscul Dis 23:75\u201399. https:\/\/doi.org\/10.1097\/cnd.0000000000000377","journal-title":"J Clin Neuromuscul Dis"},{"key":"13978_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/mus.28289","volume":"71","author":"V Bril","year":"2025","unstructured":"Bril V, Berkowicz T, Szczudlik A et al (2025) Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: a multicenter, double-blind, placebo-controlled trial. Muscle Nerve 71:43\u201354. https:\/\/doi.org\/10.1002\/mus.28289","journal-title":"Muscle Nerve"},{"key":"13978_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22:383\u2013394. https:\/\/doi.org\/10.1016\/s1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"key":"13978_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K et al (2016) International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve 54:1015\u20131022. https:\/\/doi.org\/10.1002\/mus.25198","journal-title":"Muscle Nerve"},{"key":"13978_CR19","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","volume":"78","author":"D Cella","year":"2012","unstructured":"Cella D, Lai JS, Nowinski CJ et al (2012) Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 78:1860\u20131867. https:\/\/doi.org\/10.1212\/WNL.0b013e318258f744","journal-title":"Neurology"},{"key":"13978_CR20","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.apmr.2011.01.025","volume":"92","author":"D Cella","year":"2011","unstructured":"Cella D, Nowinski C, Peterman A et al (2011) The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil 92:S28-36. https:\/\/doi.org\/10.1016\/j.apmr.2011.01.025","journal-title":"Arch Phys Med Rehabil"},{"key":"13978_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"13978_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","volume":"30","author":"YS Feng","year":"2021","unstructured":"Feng YS, Kohlmann T, Janssen MF, Buchholz I (2021) Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res 30:647\u2013673. https:\/\/doi.org\/10.1007\/s11136-020-02688-y","journal-title":"Qual Life Res"},{"key":"13978_CR23","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","volume":"10","author":"KL Gable","year":"2019","unstructured":"Gable KL, Guptill JT (2019) Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol 10:3052. https:\/\/doi.org\/10.3389\/fimmu.2019.03052","journal-title":"Front Immunol"},{"key":"13978_CR24","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s11136-020-02501-w","volume":"29","author":"T Gamst-Klaussen","year":"2020","unstructured":"Gamst-Klaussen T, Lamu AN (2020) Does the EQ-5D usual activities dimension measure what it intends to measure? the relative importance of work, study, housework, family or leisure activities. Qual Life Res 29:2553\u20132562. https:\/\/doi.org\/10.1007\/s11136-020-02501-w","journal-title":"Qual Life Res"},{"key":"13978_CR25","doi-asserted-by":"publisher","first-page":"120268","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G et al (2022) The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci 437:120268. https:\/\/doi.org\/10.1016\/j.jns.2022.120268","journal-title":"J Neurol Sci"},{"key":"13978_CR26","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"13978_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"13978_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"13978_CR29","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/s1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"13978_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s1474-4422(21)00357-4","volume":"21","author":"MG Huijbers","year":"2022","unstructured":"Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD (2022) Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol 21:163\u2013175. https:\/\/doi.org\/10.1016\/s1474-4422(21)00357-4","journal-title":"Lancet Neurol"},{"key":"13978_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M et al (2023) Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther 12:107\u2013128. https:\/\/doi.org\/10.1007\/s40120-022-00408-x","journal-title":"Neurol Ther"},{"key":"13978_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.17925\/ENR.2018.13.1.18","volume":"13","author":"S Jacob","year":"2018","unstructured":"Jacob S (2018) Refractory myasthenia gravis\u2013patient burden and the need for new therapeutic targets. Eur Neurol Rev 13:18\u201320","journal-title":"Eur Neurol Rev"},{"key":"13978_CR33","doi-asserted-by":"publisher","first-page":"1502480","DOI":"10.3389\/fimmu.2024.1502480","volume":"15","author":"O Keritam","year":"2024","unstructured":"Keritam O, Vincent A, Zimprich F, Cetin H (2024) A clinical perspective on muscle specific kinase antibody positive myasthenia gravis. Front Immunol 15:1502480. https:\/\/doi.org\/10.3389\/fimmu.2024.1502480","journal-title":"Front Immunol"},{"key":"13978_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.64719\/pb.4412","volume":"51","author":"A Khan","year":"2021","unstructured":"Khan A, Mar KF, Brown WA (2021) Consistently modest antidepressant effects in clinical trials: the role of regulatory requirements. Psychopharmacol Bull 51:79\u2013108. https:\/\/doi.org\/10.64719\/pb.4412","journal-title":"Psychopharmacol Bull"},{"key":"13978_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","volume":"105","author":"LE Ling","year":"2019","unstructured":"Ling LE, Hillson JL, Tiessen RG et al (2019) M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther 105:1031\u20131039. https:\/\/doi.org\/10.1002\/cpt.1276","journal-title":"Clin Pharmacol Ther"},{"key":"13978_CR36","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","volume":"178","author":"L Liu","year":"2007","unstructured":"Liu L, Garcia AM, Santoro H et al (2007) Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol 178:5390\u20135398. https:\/\/doi.org\/10.4049\/jimmunol.178.8.5390","journal-title":"J Immunol"},{"key":"13978_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12883-024-03553-y","volume":"24","author":"J McCallion","year":"2024","unstructured":"McCallion J, Borsi A, Noel W et al (2024) Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa. BMC Neurol 24:61. https:\/\/doi.org\/10.1186\/s12883-024-03553-y","journal-title":"BMC Neurol"},{"key":"13978_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006986.pub3","author":"MM Mehndiratta","year":"2014","unstructured":"Mehndiratta MM, Pandey S, Kuntzer T (2014) Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006986.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"13978_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs 82:865\u2013887. https:\/\/doi.org\/10.1007\/s40265-022-01726-y","journal-title":"Drugs"},{"key":"13978_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","volume":"8","author":"MN Meriggioli","year":"2012","unstructured":"Meriggioli MN, Sanders DB (2012) Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 8:427\u2013438. https:\/\/doi.org\/10.1586\/eci.12.34","journal-title":"Expert Rev Clin Immunol"},{"key":"13978_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/cnd.0000000000000156","volume":"18","author":"S Muppidi","year":"2017","unstructured":"Muppidi S (2017) Outcome measures in myasthenia gravis: incorporation into clinical practice. J Clin Neuromuscul Dis 18:135\u2013146. https:\/\/doi.org\/10.1097\/cnd.0000000000000156","journal-title":"J Clin Neuromuscul Dis"},{"key":"13978_CR42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13311-021-01175-7","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Spatola M, Schroeter CB, Wiendl H, L\u00fcnemann JD (2022) Neonatal Fc receptor-targeted therapies in neurology. Neurotherapeutics 19:729\u2013740. https:\/\/doi.org\/10.1007\/s13311-021-01175-7","journal-title":"Neurotherapeutics"},{"key":"13978_CR43","doi-asserted-by":"publisher","first-page":"116428","DOI":"10.1016\/j.jns.2019.116428","volume":"406","author":"TM Nguyen-Cao","year":"2019","unstructured":"Nguyen-Cao TM, Gelinas D, Griffin R, Mondou E (2019) Myasthenia gravis: historical achievements and the \u201cgolden age\u201d of clinical trials. J Neurol Sci 406:116428. https:\/\/doi.org\/10.1016\/j.jns.2019.116428","journal-title":"J Neurol Sci"},{"key":"13978_CR44","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B, Group MGS (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50:1778\u20131783","journal-title":"Neurology"},{"key":"13978_CR45","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.bjae.2020.07.002","volume":"20","author":"JS Perfitt","year":"2020","unstructured":"Perfitt JS, Plunkett N, Jones S (2020) Placebo effect in the management of chronic pain. BJA Educ 20:382\u2013387. https:\/\/doi.org\/10.1016\/j.bjae.2020.07.002","journal-title":"BJA Educ"},{"key":"13978_CR46","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX Randomized clinical trial. JAMA Neurol 79:1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"13978_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-025-03998-9","author":"A Raborn","year":"2025","unstructured":"Raborn A, Savord A, Houts CR et al (2025) Psychometric analysis of the neuro-QoL Fatigue in generalized myasthenia gravis (gMG) using data from a phase 3 trial. Qual Life Res. https:\/\/doi.org\/10.1007\/s11136-025-03998-9","journal-title":"Qual Life Res"},{"key":"13978_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715\u2013725. https:\/\/doi.org\/10.1038\/nri2155","journal-title":"Nat Rev Immunol"},{"key":"13978_CR49","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","volume":"270","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Barnett C, Vu T et al (2023) Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). J Neurol 270:2096\u20132105. https:\/\/doi.org\/10.1007\/s00415-022-11517-w","journal-title":"J Neurol"},{"key":"13978_CR50","doi-asserted-by":"publisher","first-page":"e16180","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, Cort\u00e9s-Vicente E, Schneider-Gold C (2024) Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol 31:e16180. https:\/\/doi.org\/10.1111\/ene.16180","journal-title":"Eur J Neurol"},{"key":"13978_CR51","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/wnl.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/wnl.0000000000002790","journal-title":"Neurology"},{"key":"13978_CR52","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/03007995.2025.2497906","volume":"41","author":"CA Scheiner","year":"2025","unstructured":"Scheiner CA, Masuda M, Hagenacker T et al (2025) Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches. Curr Med Res Opin 41:817\u2013827. https:\/\/doi.org\/10.1080\/03007995.2025.2497906","journal-title":"Curr Med Res Opin"},{"key":"13978_CR53","doi-asserted-by":"publisher","DOI":"10.1159\/000539577","author":"F Sciancalepore","year":"2024","unstructured":"Sciancalepore F, Lombardi N, Valdiserra G et al (2024) Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: a systematic review. Neuroepidemiology. https:\/\/doi.org\/10.1159\/000539577","journal-title":"Neuroepidemiology"},{"key":"13978_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.28003","volume":"69","author":"M Singer","year":"2024","unstructured":"Singer M, Khella S, Bird S et al (2024) Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events. Muscle Nerve 69:87\u201392. https:\/\/doi.org\/10.1002\/mus.28003","journal-title":"Muscle Nerve"},{"key":"13978_CR55","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/b978-0-12-823912-4.00026-8","volume":"200","author":"MR Tannemaat","year":"2024","unstructured":"Tannemaat MR, Huijbers MG, Verschuuren J (2024) Myasthenia gravis-pathophysiology, diagnosis, and treatment. Handb Clin Neurol 200:283\u2013305. https:\/\/doi.org\/10.1016\/b978-0-12-823912-4.00026-8","journal-title":"Handb Clin Neurol"},{"key":"13978_CR56","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid 1:EVIDoa2100066. https:\/\/doi.org\/10.1056\/EVIDoa2100066","journal-title":"NEJM Evid"},{"key":"13978_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang X, Mathieu M, Brezski RJ (2018) IgG Fc engineering to modulate antibody effector functions. Protein Cell 9:63\u201373. https:\/\/doi.org\/10.1007\/s13238-017-0473-8","journal-title":"Protein Cell"},{"key":"13978_CR58","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP et al (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487\u20131489. https:\/\/doi.org\/10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"key":"13978_CR59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/mlr.0000000000000447","volume":"54","author":"F Xie","year":"2016","unstructured":"Xie F, Pullenayegum E, Gaebel K et al (2016) A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care 54:98\u2013105. https:\/\/doi.org\/10.1097\/mlr.0000000000000447","journal-title":"Med Care"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13978-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13978-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13978-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:22:25Z","timestamp":1783495345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13978-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["13978"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13978-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John Vissing: Received consultant fees for serving on advisory boards for Alexion Pharmaceuticals, Argenx BV, Dianthus Therapeutics, Horizon Therapeutics (now Amgen Inc.), Janssen, Regeneron, Roche, and UCB Pharma SA. Sheryl Pease, Kayla Scippa, Kavita Gandhi, Sindhu Ramchandren and Dan Huang: Are employees of Johnson & Johnson and may hold stock or stock options in the company. Kavita Grover: Nothing to disclose. Genya Watanabe: Has received speaker honoraria from Argenx, UCB Pharma, and Alexion Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The clinical study has been approved by the appropriate ethics committee and have, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"423"}}